Teva Pharmaceutical shares jump after results beat estimates
Teva shares surge 9% after its results
Tel Aviv — Teva Pharmaceutical Industries said on Wednesday that a two-year restructuring has enabled the world’s largest generic drugmaker to turn a corner, as it reported slightly better than expected fourth-quarter results.
Its shares surged 9.1% in New York trade as the company also said it expected strong growth in two key drugs — new migraine drug Ajovy and Huntington’s treatment Austedo, in 2020 and expressed optimism over finalising a settlement in an opioid lawsuit in the US.
CEO Kare Schultz said Teva had lost the market’s confidence by missing estimates during what he said was one of the biggest restructurings in the drug sector.
“The fact we have been very predictable in our performance ... that wasn’t case in the past,” he said. “We are slowly regaining the market’s trust.”
Teva said it earned 62c per diluted share excluding one-time items in the October to December quarter, up from 53c a year earlier. Revenue rose 1% to $4.5bn, mainly due to an increase in sales of Austedo and Ajovy, as well certain respiratory products. That was partially offset by lower revenue from multiple sclerosis drug Copaxone in North America.
Analysts had forecast Teva would earn 61c per share excluding one-offs on revenue of $4.35 billion, according to data from Refinitiv.
“In 2019, we made great strides towards positioning Teva for renewed growth by completing our two-year restructuring plan, reducing our cost base by more than $3bn, and reducing our net debt by more than $9bn,” Schultz said.
SVB Leerink analyst Ami Fadia said revenue at the end of 2019 was strong, adding: “We view the top line 2020 guidance as achievable with potential for further cost savings affecting the bottom line.”
Teva has shut 13 manufacturing sites, with another 10 sites in the process of being closed or divested, and has cut its workforce by 13,000 to about 40,000.
Teva is looking to Ajovy and Austedo to boost revenue and help it pay down its debt, which at the end of 2019 stood at $26.9bn. Its debt soared after it paid more than $40bn in 2016 to buy Allergan’s generic drugs business.
Ajovy generated revenue in North America of $25m in the quarter, while sales of Austedo doubled to $136m.
Austedo has performed better than expected, Schultz said, but Ajovy sales had been lower than hoped for due to lower than expected pricing. He believes the launch of an autoinjector will boost the drug’s market share in the US migraine market to 25% from 15%.
Teva said a framework for a US settlement on opioids was still being examined. Four US states agreed in 2019 on a proposed settlement under which Teva would provide $23bn worth of generic Suboxone and pay $250m in cash over 10 years.
“We are still cautiously optimistic it can happen before the New York state trial, which is meant to start in March,” Schultz said.
For 2020 Teva forecast adjusted earnings per share of $2.30 to $2.55 and revenue of $16.6bn to $17bn.
Would you like to comment on this article or view other readers' comments?
Register (it’s quick and free) or sign in now.
Please read our Comment Policy before commenting.